抑制Hsp90 destabilizes alloreactive T细胞中的Ezh2蛋白并减轻小鼠移植物抗宿主病
本研究在小鼠GVHD模型中检验降低Ezh2介导的H3K27me3是否足以抑制GVHD。结果显示Ezh2抑制剂GSK126未能预防疾病,而Hsp90抑制剂AUY922通过 destabilizing T细胞Ezh2蛋白减少GVHD,同时保留供体T细胞的抗白血病活性并改善受体小鼠总生存。
要点
- Ezh2抑制剂GSK126虽降低H3K27me3但不影响Ezh2蛋白,未能预防小鼠GVHD。
- Hsp90抑制剂AUY922 destabilizes T细胞Ezh2蛋白,减少小鼠GVHD。
- AUY922保留供体T细胞抗白血病活性,改善异基因HSCT后受体小鼠总生存。
核心结论
- Ezh2-Hsp90相互作用是T细胞应答所需且先前未被认识到的机制,也是控制GVHD的有效靶点。
研究设计与样本
- 在小鼠GVHD模型中检验假说,使用Ezh2抑制剂GSK126和Hsp90抑制剂AUY922进行干预。
主要发现
- 给予Ezh2抑制剂GSK126特异性降低H3K27me3而不影响Ezh2蛋白,未能预防疾病。
- 使用Hsp90特异性抑制剂AUY922 destabilizes T细胞Ezh2蛋白,减少接受异基因HSCT小鼠的GVHD。
- 体内给予AUY922选择性诱导活化T细胞凋亡,并减少产生干扰素γ和肿瘤坏死因子α的效应细胞,类似于Ezh2基因缺失。
- 将Ezh2导入同种反应性T细胞可恢复AUY922处理后的扩增和效应细胞因子产生,提示抑制Hsp90受损的T细胞同种反应性主要通过耗尽Ezh2实现。
- Ezh2的酶性SET结构域直接与Hsp90相互作用,防止活化T细胞中Ezh2快速降解。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Modulating T-cell alloreactivity has been a main strategy to reduce graft-versus-host disease (GVHD), a life-threatening complication after allogeneic hematopoietic stem-cell transplantation (HSCT). Genetic deletion of T-cell Ezh2, which catalyzes trimethylation of histone H3 at lysine 27 (H3K27me3), inhibits GVHD. Therefore, reducing Ezh2-mediated H3K27me3 is thought to be essential for inhibiting GVHD. We tested this hypothesis in mouse GVHD models. Unexpectedly, administration of the Ezh2 inhibitor GSK126, which specifically decreases H3K27me3 without affecting Ezh2 protein, failed to prevent the disease. In contrast, destabilizing T-cell Ezh2 protein by inhibiting Hsp90 using its specific inhibitor AUY922 reduced GVHD in mice undergoing allogeneic HSCT. In vivo administration of AUY922 selectively induced apoptosis of activated T cells and decreased the production of effector cells producing interferon γ and tumor necrosis factor α, similar to genetic deletion of Ezh2. Introduction of Ezh2 into alloreactive T cells restored their expansion and production of effector cytokines upon AUY922 treatment, suggesting that impaired T-cell alloreactivity by inhibiting Hsp90 is achieved mainly through depleting Ezh2. Mechanistic analysis revealed that the enzymatic SET domain of Ezh2 directly interacted with Hsp90 to prevent Ezh2 from rapid degradation in activated T cells. Importantly, pharmacological inhibition of Hsp90 preserved antileukemia activity of donor T cells, leading to improved overall survival of recipient mice after allogeneic HSCT. Our findings identify the Ezh2-Hsp90 interaction as a previously unrecognized mechanism essential for T-cell responses and an effective target for controlling GVHD.
引用
- Huang Q, He S, Tian Y, et al. Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice. Blood. 2017. PMID: 28246193. doi:10.1182/blood-2016-08-735886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。